Abstract-Nitric oxide (NO) is an essential vasodilator. In vascular diseases, oxidative stress attenuates NO signaling by both chemical scavenging of free NO and oxidation and downregulation of its major intracellular receptor, the ␣␤ heterodimeric heme-containing soluble guanylate cyclase (sGC). Oxidation can also induce loss of the heme of sGC, as well as the responsiveness of sGC to NO. sGC activators such as BAY 58-2667 bind to oxidized/heme-free sGC and reactivate the enzyme to exert disease-specific vasodilation. Here, we show that oxidation-induced downregulation of sGC protein extends to isolated blood vessels. Mechanistically, degradation was triggered through sGC ubiquitination and proteasomal degradation. The heme-binding site ligand BAY 58-2667 prevented sGC ubiquitination and stabilized both ␣ and ␤ subunits. Collectively, our data establish oxidation-ubiquitination of sGC as a modulator of NO/cGMP signaling and point to a new mechanism of action for sGC activating vasodilators by stabilizing their receptor, oxidized/heme-free sGC. O ne major risk factor for the development of cardiovascular diseases, such as coronary heart disease, stroke, and myocardial infarction, is an imbalance of the production and elimination of reactive oxygen species, also termed as oxidative stress. [1][2][3] As a consequence, the nitric oxide (NO)/ cGMP signaling cascade is impaired, eg, through the excessive production of superoxide, which reacts with NO in a diffusion-limited reaction, yielding peroxynitrite. 4 The biological impact of NO scavenging is further aggravated by the progressive inhibition and downregulation of the NO receptor soluble guanylate cyclase (sGC). [5][6][7][8][9] Circumstantial evidence has implicated proteasomal pathways in this downregulation of sGC. 10 -12 Conversely, a novel class of sGC activators, represented by BAY 58-2667, are potentiated under oxidative stress conditions and represent thus an entirely new diseasespecific vasodilator class. 13 sGC is a heterodimer consisting of an ␣ and a Fe 2ϩ /hemecontaining ␤ subunit that complexes NO with high affinity and specificity. 14 Binding of NO to the Fe 2ϩ /heme results in allosteric activation of the enzyme and enhanced conversion of GTP into the vasorelaxant and antiproliferative second messenger cGMP. 14,15 In vitro experiments have demonstrated that oxidation of sGC heme to its ferric (Fe 3ϩ ) form by the sGC inhibitor 1H-[1,2,4]-oxadiazolo [3,4-a]quinoxalin-1-one (ODQ) attenuates NO-mediated cGMP production, suggesting that the ferro (Fe 2ϩ ) form of sGC is crucial for activation by NO. 16 -18 In addition, studies with primary endothelial and smooth muscle cells have revealed that, within 24 hours, ODQ causes a dramatic decrease in sGC protein levels. 13 Similar results were obtained with other oxidizing compounds such as methylene blue or the peroxynitrite donor 1,3-morpholino-sydnonimine hydrochloride (SIN-1), indicating that oxidative stress triggers downregulation of sGC protein levels. 13 At present, the molecular mechanisms under...

Regulator of G-protein signaling 18 (RGS18) is a GTPase-activating protein for the G-␣-q and G-␣-i subunits of heterotrimeric Gproteins that turns off signaling by G-protein coupled receptors. RGS18 is highly expressed in platelets. In the present study, we show that the 14-3-3␥ protein binds to phosphorylated serines 49 and 218 of RGS18. Platelet activation by thrombin, thromboxane A2, or ADP stimulates the association of 14-3-3 and RGS18, probably by increasing the phosphorylation of serine 49. In contrast, treatment of platelets with prostacyclin and nitric oxide, which trigger inhibitory cyclic nucleotide signaling involving cyclic AMP-dependent protein kinase A (PKA) and cyclic GMP-dependent protein kinase I (PKGI), induces the phosphorylation of serine 216 of RGS18 and the detachment of 14-3-3. Serine 216 phosphorylation is able to block 14-3-3 binding to RGS18 even in the presence of thrombin, thromboxane A2, or ADP. 14-3-3-deficient RGS18 is more active compared with 14-3-3-bound RGS18, leading to a more pronounced inhibition of thrombin-induced release of calcium ions from intracellular stores. Therefore, PKA-and PKGI-mediated detachment of 14-3-3 activates RGS18 to block Gq-dependent calcium signaling. These findings indicate cross-talk between platelet activation and inhibition pathways at the level of RGS18 and Gq. IntroductionIn healthy vasculature, endothelial cells lining the blood vessels constantly produce and release prostacyclin (PGI 2 ) and nitric oxide (NO) into the vessel lumen. The interaction of endothelial factors with platelets plays a fundamental role in controlling hemostasis and in maintaining platelets in a resting state. Platelet inhibition by both PGI 2 and NO has been well established. The signaling pathways of both molecules result in an elevation of cyclic nucleotides that activate cyclic AMP-dependent protein kinase A (PKA) and cyclic GMP-dependent protein kinase I (PKGI). These in turn phosphorylate an unknown number of substrate proteins, resulting in reduced release of calcium ions (Ca 2ϩ ) from intracellular stores and reduced activation of G-proteins such as Rap1, ultimately leading to a block of platelet adhesion, granule release, and aggregation. PKA and PKGI have overlapping substrate specificities, which may explain the synergistic role of the 2 pathways. Few substrates have been established in platelets, among them Rap1GAP2, a GTPase-activating protein (GAP) of the small G-protein Rap1, as we have shown previously. 1 Other substrates include vasodilator-stimulated phospho-protein (VASP), heatshock protein 27 (HSP27), and LIM and SH3 domain protein (LASP), all of which regulate actin dynamics. 2,3 The IP 3 -receptor and the IP 3 -receptor-associated G-kinase substrate (IRAG) are the only PKA and/or PKGI substrates that have been shown to mediate cAMP/cGMP effects on intracellular Ca 2ϩ release. [2][3][4] Limited data are available on the specific substrates and signaling events that translate PKA/G substrate phosphorylation into platelet inhibition.Conversely, bindin...

Key Points• ECM is associated with an early marked increase in plasma VWF levels and accumulation of UL-VWF multimers.• Following P berghei infection, VWF 2/2 mice survive significantly longer compared with WT controls.Plasmodium falciparum malaria infection is associated with an early marked increase in plasma von Willebrand factor (VWF) levels, together with a pathological accumulation of hyperreactive ultra-large VWF (UL-VWF) multimers. Given the established critical role of platelets in malaria pathogenesis, these increases in plasma VWF raise the intriguing possibility that VWF may play a direct role in modulating malaria pathogenesis. To address this hypothesis, we used an established murine model of experimental cerebral malaria (ECM), in which wild-type (WT) C57BL/6J mice were infected with Plasmodium berghei ANKA. In keeping with findings in children with P falciparum malaria, acute endothelial cell activation was an early and consistent feature in the murine model of cerebral malaria (CM), resulting in significantly increased plasma VWF levels. Despite the fact that murine plasma ADAMTS13 levels were not significantly reduced, pathological UL-VWF multimers were also observed in murine plasma following P berghei infection. To determine whether VWF plays a role in modulating the pathogenesis of CM in vivo, we further investigated P berghei infection in VWF 2/2 C57BL/6J mice. Clinical ECM progression was delayed, and overall survival was significantly prolonged in VWF 2/2 mice compared with WT controls. Despite this protection against ECM, no significant differences in platelet counts or blood parasitemia levels were observed between VWF 2/2 and WT mice. Interestingly, however, the degree of ECMassociated enhanced blood-brain barrier permeability was significantly attenuated in VWF 2/2 mice compared with WT controls.Given the significant morbidity and mortality associated with CM, these novel data may have direct translational significance. (Blood. 2016;127(9):1192-1201) IntroductionPlasmodium falciparum malaria remains a major cause of morbidity and mortality among children in sub-Saharan Africa. [1][2][3] Although the biological mechanisms involved in the pathophysiology of severe P falciparum malaria remain poorly understood, previous studies have demonstrated that sequestration of P falciparum-infected erythrocytes (IEs) within the microvasculature of the brain is important in the development of cerebral malaria (CM). 4,5 This sequestration involves adhesion of IE to host vascular endothelial cell (EC) surfaces [6][7][8] and is mediated by a variety of specific EC adhesion molecules including CD36, intercellular adhesion molecule-1, and thrombospondin. 9 Moreover, recent studies have also demonstrated that the endothelial protein C receptor also plays an important role in modulating the sequestration of IE. 10 In addition to IE, sequestration of leukocytes and platelets within the cerebral microvasculature has also been reported in postmortem samples from CM patients. 11,12Von Willebrand factor (VWF)...